Five Prime Therapeutics, Inc. FPRX Income Statement

Five prime therapeutics, inc. (FPRX)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Sep'12
Revenue:
Revenue from contracts with customers
-	-	2,984	3,333	-	4,031	5,771	7,580	32,486	-	8,333	7,822	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total revenue
8,414	-	-	-	5,347	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration revenue
-	-	-	-	-	-	-	-	-	-	-	-	10,135	-	6,680	9,229	6,520	363,341	5,858	6,315	4,287	-	6,059	-	-	-	-	-	-	-
Collaboration and license revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,981	-	-	-	-	-	-
Collaboration revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,546	-	3,482	3,549	2,975	2,862
Operating expenses:
Research and development
18,556	25,937	26,948	29,425	31,753	34,733	44,687	33,380	43,552	32,671	42,733	41,744	33,760	29,149	23,890	22,177	18,856	20,956	24,720	13,310	11,211	12,571	9,803	11,873	8,926	8,077	8,193	8,585	7,930	6,510
General and administrative
10,491	9,372	13,206	9,661	10,510	9,579	9,832	9,782	10,478	10,479	9,674	9,363	10,486	10,522	9,146	8,106	8,057	8,602	5,213	4,596	4,220	3,968	3,360	3,024	3,280	3,042	2,607	2,386	2,392	2,257
Total operating expenses
29,047	35,309	40,154	39,086	42,263	44,312	54,519	43,162	54,030	43,150	52,407	51,107	44,246	39,671	33,036	30,283	26,913	29,558	29,933	17,906	15,431	16,539	13,163	14,897	12,206	11,119	10,800	10,971	10,322	8,767
Loss from operations
-20,633	-32,099	-37,170	-35,753	-36,916	-40,281	-48,748	-35,582	-21,544	-29,932	-44,074	-43,285	-34,111	-31,409	-26,356	-21,054	-20,393	333,783	-24,075	-11,591	-11,144	-11,894	-7,104	-9,916	-8,660	-7,334	-7,318	-7,422	-7,347	-5,905
Interest income
517	744	1,100	1,363	1,533	1,580	1,531	1,522	1,159	-	792	702	-	-	-	-	-	-	-	117	108	62	57	55	36	27	7	13	15	21
Other expense, net
-	-	-	1	-	-	-	0	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest and other income, net
-	-	-	-	-	-	-	-	-	-	-	-	668	-	639	646	536	-	104	-	-	-	-	-	-	-	-	-	-	-
Other expense, net
-	-	1	-	-2	-	-27	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-41	-5	-20	-10	77	135	285	-
Loss before income tax
-20,116	-31,357	-36,069	-34,391	-35,385	-38,753	-47,244	-34,060	-20,390	-29,210	-43,282	-42,583	-33,443	-30,763	-25,717	-20,408	-19,857	333,938	-23,971	-11,474	-11,036	-	-	-	-	-	-	-	-	-
Income tax provision
-	-	-	-	-	-	-	-	-	-	-	1,703	-	-10,657	-6,303	-7,271	-6,817	37,810	0	0	0	-	-	-	-	-	-	-	-	-
Other income, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26
Net loss
-20,116	-31,357	-36,069	-34,391	-35,385	-38,753	-47,244	-34,060	-20,390	-29,211	-43,282	-44,286	-33,443	-20,106	-19,414	-13,137	-13,040	296,128	-23,971	-11,474	-11,036	-11,826	-7,088	-9,866	-8,644	-7,317	-7,234	-7,274	-7,047	-5,858
Basic and diluted net loss per common share
-0.57	-0.88	-1.03	-0.99	-1.02	-1.14	-1.37	-0.99	-0.63	-1.05	-1.54	-1.58	-1.21	-0.74	-0.72	-0.49	-0.49	-	-0.93	-0.45	-0.44	-	-0.33	-0.46	-0.46	-	-2.74	-5.82	-5.73	-4.85
Weighted-average shares used to compute basic and diluted net loss per common share
35,263	35,181	34,996	34,909	34,794	34,707	34,482	34,401	32,314	28,157	28,020	27,946	27,657	27,406	27,139	26,924	26,351	-	25,825	25,690	25,072	-	21,521	21,465	18,841	-	2,637	1,250	1	1
Collaboration revenue [Member]
Total revenue
3,414	-	-	-	5,347	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License revenue [Member]
Total revenue
5,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-